Syntax Bio
Regenerative Medicine · Cell & Gene Therapy
Series Alatest round · Jun 2026 · 4 mo ago
1backers · Illumina Ventures
$237kgrants · 1 grant · CORDIS
50+team · employees, estimated range
Overview
Syntax Bio is a synthetic biology company programming the next generation of stem cell-derived therapies and organoids.
Funding and backers
Latest round
Series A
Jun 2026 · 4 mo ago
Team
51-200
employees, estimated range
Grants
$237k
1 grant · CORDIS
Backers
1
Illumina Ventures
The money's age
Fresh money
4 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 23
Partnership Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation · YahooFinance
Jun 21
Raised a round Series A · YahooFinance
Jun 9
Partnership Syntax Bio Announces Collaboration with Mayo Clinic to Advance Pancreatic Cell Therapy for Type 1 Diabetes · AOL.com
Sep 1, 2021
Won a grant $237k · CORDIS
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Jun 2026 | — | — | YahooFinance |
| Grant | Sep 2021 | $237k | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
High purity, bioactive recombinant cytokine proteins and growth factors made for stem cell, organoid and regenerative medicine.
Developing next-generation cell therapies utilizing engineered biomaterial technologies.
Cellcolabs produces GMP mesenchymal stem cells (MSCs) for clinical research and collaboration with clinics and scientists worldwide.
The growth of Revatis is supported by its innovative and patented technology to obtain multipotent adult mesenchymal stem cells from a…
Cellino is a Massachusetts biotechnology company founded in 2017. It automates stem cell manufacturing with laser editing, imaging and…
Pelage Pharmaceuticals is developing PP405, a topical treatment designed to reactivate dormant hair follicle stem cells and restore natural…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Illumina VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation
CHICAGO & MILPITAS, Calif., June 23, 2026--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, tod
Read more
Report
Report
Syntax Bio Raises $14.4 Million Series A And Announces Leadership Appointments
Syntax Bio announced an expanded Series A round and several leadership appointments across its executive team, board of directors, and scientific advisory board. The expanded round brings Syntax Bio's Series A to $14.4 million and total funding to more th
Read more
Report
Syntax Bio, Ajinomoto Health & Nutrition North America, Inc. Collaborate to Evaluate Stem Cell Culture Technologies Using Cellgorithm Platform - AOL
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chicago
United States
HQ
50-200 est. staff